Search

Your search keyword '"Masters C"' showing total 126 results

Search Constraints

Start Over You searched for: Author "Masters C" Remove constraint Author: "Masters C" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
126 results on '"Masters C"'

Search Results

3. Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials

5. Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force

7. Accuracy of TrUE-Net in comparison to established white matter hyperintensity segmentation methods: An independent validation study.

11. 12415 Surgical Management of Undescended Gonads for Androgen Insensitivity Syndrome.

18. Plasma amyloid-beta levels in a pre-symptomatic Dutch-type hereditary cerebral amyloid angiopathy pedigree: A cross-sectional and longitudinal investigation

19. RP25- Sigmoid methodology allows early prediction of cognitive decline towards Alzheimer's disease across several cognitive domains

21. Amyloid and tau pathology associations with personality traits, neuropsychiatric symptoms, and cognitive lifestyle in the preclinical phases of sporadic and autosomal dominant Alzheimer’s disease

22. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

24. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease

25. Klotho allele status is not associated with Aß and APOE e4–related cognitive decline in preclinical Alzheimer's disease

26. A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease

27. KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aß-amyloid burden

28. Trajectories of depressive and anxiety symptoms in older adults: a 6-year prospective cohort study

29. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.

30. Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies

33. Reduced TRPC6 mRNA levels in the blood cells of patients with Alzheimer’s disease and mild cognitive impairment

34. PET-only 18F-AV1451 tau quantification

35. Imaging of tau deposits in adults with Niemann-Pick type C disease: a case-control study.

36. Modulation of retinal arteriolar central reflection by APOE Genotype

37. Amyloid ß–associated cognitive decline in the absence of clinical disease progression and systemic illness

38. BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF

39. Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults

40. Increased Carbohydrate Intake is Associated with Poorer Performance in Verbal Memory and Attention in an APOE Genotype-Dependent Manner

41. β-Amyloid, APOE and BDNF genotype, and depressive and anxiety symptoms in cognitively normal older women and men

42. Corrigendum to ‘Self and informant memory concerns align in healthy memory complainers and in early stages of mild cognitive impairment but separate with increasing cognitive impairment’

43. Plasma phospholipid and sphingolipid alterations in presenilin1 mutation carriers: A pilot study

44. ß-Amyloid, APOE and BDNF Genotype, and Depressive and Anxiety Symptoms in Cognitively Normal Older Women and Men

45. Impact of Mild Head Injury on Neuropsychological Performance in Healthy Older Adults: Longitudinal Assessment in the AIBL Cohort

46. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.

47. Longitudinal cognitive decline in the AIBL cohort: The role of APOE e4 status

48. APOE ε4 Moderates Amyloid-related Memory Decline In Preclinical Alzheimer's Disease

49. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated In Pet Amyloid-β Characterized Subjects From The Australian Imaging, Biomarkers And Lifestyle (AIBL) Study

50. Novel Statistically-Derived Composite Measures for Assessing The Efficacy of Disease-Modifying Therapies In Prodromal Alzheimer's Disease Trials: An AIBL Study

Catalog

Books, media, physical & digital resources